INTRODUCTION
In many first world countries, hepatitis C emerged as a major public-health issue in the 1990s. Seroprevalence surveys have been carried out in various populations, especially among at-risk populations such as blood recipients [I] and injecting drug users (IDUS) [2-51. In France, HCV seroprevalence was estimated in 1994 at 1.2% of the general population [6, 7] . The prevalence of serum antibodies to hepatitis C virus (HCV) among IDUs was found to be 72% and 67% in northern and southwestern France respectively [8, 9] .
A previous study carried out in the largest prison in southeastern France showed that prisoners very often reported risk behavior before incarceration (injecting drug use, multiple sexual partners, sex with IDUs or with HN-seropositive partners) [lo] and during incarceration as well [ll] . Whereas H N seroprevalence has already been investigated in some European prisons, including southeastern France , the prevalence of serologic markers against HCV among European prisoners is still poorly documented. Some surveys carried out among Italian and Norwegian prisoners found highlevels ofHCV seroprevalence [15, 16] . Only one survey has been carried out among French incarcerated IDUs, in whom HCV seropositivity was found to be 80% [17] .
Because the size of the prison population, especially injectors, has dramatically increased in the majority of developed countries, it is necessary to evaluate the need for implementing screening programs and to find appropriate resources to implement them in a context of limited funding and s&.
We carried out such a survey to evaluate a hepatitis B immunization program, the results of which have already been published [18] . Another objective of that study was to estimate the seroprevalence of antibodies against HCV and HIV, and to record related factors.
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M€IHODS
French prisoners are routinely offered HIV counseling on entry into prison. HIV and syphilis screening are also offered in this context at the STD clinic by a physician who is independent of the prison administration, but, whereas syphilis testing is mandatory for ill sentenced persons, HIV testing is not. These tests are h e and anonymous: the penitentiary administration is not told the inmates' serostatus; and the laboratory which tests the sera sees only numerical codesthese are Werent &om the identification numbers given by the penitentiary administration when the inmates are incarcerated. The medical chief of the prison, who is also independent of the prison administration, is informed by the physician of the STD clinic only ?fter the inmates have given their consent.
The prison in Marseilles is one of the largest French prisons and holds about 2000 prisoners, 75% on remand (awaiting trial) and 25% on short-term sentences. Between March and December 1995, we invited male and female new entrants to participate in a seroprevalence survey for markers of viral hepatitis B and C, and to be immunized against hepatitis B. Due to limited staf€ and funding resources, but to ensure sufticient statistical power, all women were invited, but only every second male new inmate was invited to participate in the survey. To avoid selection bias, the physicians invited only those male entrants who had an even identification number. This number is a routine one given by the penitentiary administration and not by the medical staf€. Prisoners transferred h m another prison or incarcerated in high-security cells (<0.5% of the imprisoned population) were excluded h m the study. prelirmnary information on the objectives of the study was posted in different places in the prison. The physician who offered serologic testing and immunization was independent of the penitentiary administration and was not obliged to communicate testing results to the administration. Each participant gave written consent. A standardized face-to-face questionnaire was completed by the physicians to establish socio- Statistical analysis was performed using the chisquare test for univariate analysis and the logistic regression model for multivariate analysis (Statistical Package for Social Sciences 7.5).
RESULTS
Among the 441 eligible prisoners, 391 (89%) agreed to participate in the survey; 75% were aged 18-35 years, 21% were women, 83% lived in Marseilles, 56% were unemployed, 71% had less than 12 years of education, 41% reported that they had no health insurance, and 34% had been incarcerated at least once before and were known to the physicians providmg counsehng and testing in the prison. Participants and non-participants did not differ sigtllficantly in socio-demographic characteristics and risk behavior (including injecting drug use); in particular, the proportion of participants who had ever been tested for HCV did not differ (12% versus 15%, p 0 . 7 ) . Immunization against hepatitis B was declared more fiequently by participants than by non-participants (men 14% versus 8% (p=O.O4); women 33% versus 18% (p=0.09)).
Sexual and injecting behavior
Men reported having had more than one sexual partner during the last 12 months more hquently than did women (47% versus 23% pC10-2); however, women reported having had sexual intercourse with an IDU partner more fi-equently than did men (20% versus 8%;
Twenty-three per cent of inmates (891391) declared that they had injected drugs at some time. This behavior was more fi-equently declared by women than by men, especially during the last 12 months (25% versus 16%; p 0 . 0 6 ) . Syringe and needle sharing during the last 12 months was fi-equently reported by both men and women (24% versus 35%; ~~0 . 3 2 ) ; spoon and filter sharing was reported sigdcantly more often by women than by men (60% versus 29%; p=0.02). The
pc10-2).
proportion of lDUs who declared that they had had two or more heterosexual partners during the last 12 months or had had homosexual intercourse did not difGer fiom that of non-IDUs ( 
DISCUSSION
T h i s survey underlines the fact that the hgh prevalence of risk behavior is common, and there is high HCV and HIV seroprevalence among people entering southeastern French prisons. About 27% of incarcerated persons were seropositive for HCV, i.e. 20 times the proportion in the French general population (1.2%) [6, 7] . In our study, the HCV seroprevalence among IDU inmates was exceedingly high and in agreement with estimates reported by other studies carried out among fiee-living IDUs in northern France (72%) [8] , in southwestern France (67%) [9] , and in North America (77%) [S] . It was also in agreement with studies carried out among imprisoned IDUs in northern France (80%), A u s d a (66%), Austria (75%), Italy (59%) and Germany (83%) [ 3,4,16,17,19] .
In our survey, the participation rate was high (89%). Reporting a history of hepatitis B, and previous testing for HCV and HIX &d not W e r sigrufcantly between participants and non-participants, which implies that conclusions are lkely to be reliable. Although we cannot eliminate some selection bias, because vaccination O u r study showed that, in spite of the high HCV seroprevalence, a minority of prisoners h a d y knew their HCV serostatus. It is worthwhile emphasizing that many IDUs and HIV-positive prisoners had never been screened for HCV before the current incarceration or were not aware of their HCV serostatus. Imprisonment might be an opportunity to counsel and screen persons who are at risk of contracting HCV and have limited access to health care. Our study showed that HCV testing was well accepted by inmates and that IDUs who had been previously incarcerated were more often screened for HCR However, the implementation of an HCV screening program needs extra resources to train physicians and nurses, to offer costly investigations and therapies (interferon-a and ribavirin), to educate stA€ and prisoners on the risks of contamination, and to avoid stigmatizing HCV-infected inmates. As the proportion of IDUs in French prisons, as in most prison systems, is not well documented and very likely to fluctuate over time and in local situations, we do not have reliable estimates of the number of HCV positives who should be referred and treated. On the basis of a conservative estimate of 15% IDUs in French prisons, we can estimate that about 8000 IDU inmates are infected with HCR If we add the number of non-IDU inmates potentially infected with HCV (7% in our sample), then we can estimate that a total of 11 500 inmates should be referred, i.e. about 20% of the 60 OOO people incarcerated in French prisons on a given day. These elements should be confirmed by M e r epidemiologic and cost-effectiveness studies, but they should encourage decision-makers to consider seriously the issue of hepatitis C in prison as a major publichealth problem.
The reported HIV seroprevalence was lower than that observed in 1992 in the same prison by very similar methods (men 5.9% versus 9%; women 6.4% versus 13.1%) [14] . Since 1990, a decrease in the proportion of HIV-infected prisoners has also been observed by the national survey undertaken by the Ministry of Justice annually on a specified day 
